Glizamide 40 Tablet contains Gliclazide IP 40mg, a sulfonylurea class oral antidiabetic agent designed to regulate blood glucose in type 2 diabetes patients. It enhances insulin secretion from pancreatic beta cells, assisting in effective glycemic control.
This tablet falls under the diabetes care segment, providing a reliable oral therapy alongside dietary and lifestyle interventions. Its 40mg dose is suitable for titration or maintenance therapy depending on patient requirements.
Glizamide 40 Tablet is commonly prescribed by endocrinologists, general physicians, hospitals, and clinics, ensuring strong demand for PCD pharma distribution. Its proven efficacy and patient-friendly dosing encourage repeat prescriptions and high compliance.
For PCD pharma franchise and B2B partners, Glizamide 40 Tablet offers a profitable business opportunity. With consistent demand in hospitals, clinics, and retail pharmacies, it is ideal for domestic distribution, export, and third-party manufacturing, guaranteeing sustainable growth and attractive margins.